|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C12N 9/24 | (2006.01) | ||
| C07K 16/32 | (2006.01) |
| (11) | Number of the document | 2806892 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13701871.9 |
| Date of filing the European patent application | 2013-01-25 | |
| (97) | Date of publication of the European application | 2014-12-03 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-06 |
| (46) | Date of publication of the claims translation | 2019-07-25 |
| (86) | Number | PCT/GB2013/050164 |
| Date | 2013-01-25 |
| (87) | Number | WO 2013/110946 |
| Date | 2013-08-01 |
| (30) | Number | Date | Country code |
| 201201314 | 2012-01-26 | GB |
| (72) |
CRISPIN, Matthew David Max, GB
SCANLAN, Christopher Neil, GB
|
| (73) |
Hansa Biopharma Limited,
Ashcombe Court, Woolsack Way, Godalming, Surrey, GU7 1LQ,
GB
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kombinuota terapija, panaudojant antikūnus ir endoglikozidazes |
| COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES |
| Payment date | Validity (years) | Amount | |
| 2023-01-17 | 11 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-01-25 |